Intellect Neurosciences’ CEO talks about the day-to-day struggles of a small biotech trying to develop drugs for neurodegenerative diseases. Among its successes is an out-licensing deal with ViroPharma to develop Intellect’s OX1 for Friedreich’s Ataxia. Similar to metal-binding compounds being developed by Prana and Varinel, OX1 is a potent anti-oxidant with purported ability to bind iron and minimize free radical damage. Given its mechanism of action, OX1 may be therapeutically relevant for ALS.
Click here to read more.Share this: